Also known as: Entyvio, ENTYVIO
Abivax aligned with FDA on obefazimod NDA strategy for ulcerative colitis, targeting filing by end‑2026. Phase 3 ABTECT data at ECCO 2026 showed early symptom relief and positive DSMB safety review. Leadership appointments support potential commercialization.
Takeda reported positive ENTYVIO pediatric data, secured FDA Priority Review for oveporexton, and expanded AI drug discovery. Shares trade at ¥5,609; analyst fair value is about ¥5,263.
Risankizumab data in Crohn’s disease showed 55% clinical remission at week 12 in AFFIRM, durable efficacy through 148 weeks in SEQUENCE, and the lowest 24-month switch rate in a U.S. claims analysis.
Alvotech announced successful clinical trial results for AVT80, a biosimilar to Takeda's Entyvio, meeting all primary endpoints. The company targets a $6.4 billion market opportunity with regulatory submissions planned.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07694674 |
Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease |
RECRUITING | |
| NCT07665294 |
Combination CurQD and Vedolizumab in Ulcerative Colitis |
NOT_YET_RECRUITING | PHASE4 |
| NCT07619898 |
PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid Exposure |
NOT_YET_RECRUITING | PHASE2 |
| NCT07442045 |
Real-World Effectiveness and Safety of Upadacitinib Plus Vedolizumab vs Upadacitinib Monotherapy During Induction in Moderate-to-Severe Ulcerative Colitis |
RECRUITING | |
| NCT06880744 |
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06815003 |
Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning |
RECRUITING | PHASE2 |
| NCT06443502 |
A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis |
RECRUITING | PHASE3 |
| NCT06317220 |
Vedolizumab for the Treatment of Collagenous Gastritis |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06095128 |
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) |
RECRUITING | PHASE4 |
| NCT06045754 |
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease |
RECRUITING | PHASE4 |
